Compare RYTM & SSRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | SSRM |
|---|---|---|
| Founded | 2008 | 1946 |
| Country | United States | United States |
| Employees | 414 | 2900 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.5B |
| IPO Year | 2017 | N/A |
| Metric | RYTM | SSRM |
|---|---|---|
| Price | $87.63 | $30.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $131.14 | $32.74 |
| AVG Volume (30 Days) | 713.2K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.34 | $56.48 |
| Revenue Next Year | $86.06 | $4.31 |
| P/E Ratio | ★ N/A | $14.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.71 | $10.78 |
| 52 Week High | $122.20 | $36.52 |
| Indicator | RYTM | SSRM |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 47.43 |
| Support Level | $87.19 | $21.71 |
| Resistance Level | $92.17 | $33.49 |
| Average True Range (ATR) | 5.01 | 1.59 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 41.38 | 32.68 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.